Список литературы

47. Lee-Kirsch MA. The type I interferonopathies. Ann. Rev. Med. 2017; 68.

48. Bogunovic D, Byun M, Durfee LA, Abhyankar A et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012; 337: 1684-1688.

49. Zhang X, Bogunovic D, Payelle-Brogard B, Francois- Newton V et al. Human intracellular ISG15 prevents interferon- a/b over-amplification and auto-inflammation. Nature. 2015; 517 (7532): 89-93.

50. Meuwissen MEC, Schot R, Buta S, Oudesluijs G, Tinschert S et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 2016;213:1163-1174.

51. Anja Basters, Klaus-Peter Knobeloch, Gunter Fritz. USP18 - a multifunctional component in the interferon response. Bioscience Reports Nov 16, 2018.

52. Fabre A, Charroux B, Martinez-Vinson C, et al. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am J Hum Genet 2012;90:689-92.

53. Fabre A, Martinez-Vinson C, Goulet O, et al. Syndromic diarrhea/Tricho-hepato-enteric syndrome. Orphanet J Rare Dis 2013 ;8:5.

54. Eckard SC, Rice GI, Fabre A, et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol 2014;15:839-45.

55. https://www.orpha.net.

56. Bienias M, Bruck N, Griep C, Wolf C, Kretschmer S, Kind B, Tungler V, Berner R, Lee-Kirsch MA. Therapeutic Approaches to Type I Interferonopathies. Curr Rheumatol Rep. 2018 Apr 20;20(6):32.

57. Davidson S, Steiner A, Harapas CR, Masters SL. An Update on Autoinflammatory Diseases: Interferonopathies. Curr Rheumatol Rep. 2018 May 30;20(7):38.

58. Kato H, Oh SW, Fujita T. RIG-I-Like Receptors and Type I Interferonopathies. J Interferon Cytokine Res. 2017 May;37(5):207-213.

59. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017 Dec;49:96-102.

60. Eleftheriou D, Brogan PA. Genetic interferonopathies: An overview. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):441-459

61. Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127.

62. Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendmez F, Hernandez A, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol (2010) 62:489-95.

63. Khamashta M, Merrill JT, Werth VP, Furie P, et al. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study // Ann Rheum Dis. 2016 Nov; 75(11): 1909-1916.

64. Rice G, Forte GMA, Szynkiewicz M, Chase DS et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and ADAR: a case-control study // Lancet Neurol. 2013 Dec;12(12): 11591169.

65. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711-23.

66. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-5.

67. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1-2):59-68.

68. Rice G, Patrick T, Parmar R, Taylor CF et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome // Am J Hum Genet. 2007b ;81:713-25.

69. Брюханова Н.О., Жилина С.С., Айвазян С.О., Ананьева Т.В., Беленикин М.С., Кожанова Т.В., Мещерякова Т.И., Зинченко Р.А., Мутовин Г.Р., Заваденко Н.Н. Синдром Айкарди-Гутьерес у детей с идиопатической эпилепсией. Российский вестник перинатологии и педиатрии. 2016;61(2):68-75.

70. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fremond ML, Nitschke P, Molina TJ, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124:5516-5520.

71. Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P. Standing A, Eleftheriou D, Klein N, Brogan PA. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol. 2015; 67:808.

72. Munoz J, Rodiere M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, Rozenberg F, Crow YJ, Bessis D. Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood Granulomatosis with Polyangiitis. JAMA Dermatol. 2015; 151:872-877.

73. Chia J, Eroglu FK, Ozen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, Goldbach-Mansky R, Cowen EW. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016; 74:186-189.

74. J Kluk, M Rustin, PA Brogan, E Omoyinmi, DM Rowczenio, LC Willcocks, L Melly, and HJ Lachmann. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a report of a novel mutation and review of the literature. Br J Dermatol. 2014 Jan; 170(1): 215-217.

75. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation. Eur J Pediatr. 2016 May;175(5):735-40.

76. Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis. Rev Neurol. 2018 Jan 1;66(1):25-32.

77. Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING //Ann Rheum Dis. 2017;76(2):468-472.

78. Rodero MP. Fremond M-L, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy.// Ann Rheum Dis 2016 ;75(12):e75-5.

79. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014 Dec ;73(12)

80. Li Y, Wilson HL, Kiss-Toth E. Regulating STING in health and disease. J Inflamm (Lond). 2017 Jun 7;14:11.

81. Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, Brogan PA, Rice GI, Crow YJ, Dale RC. An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation // Neurology. 2018 Feb 6 ;90(6):289-291.

82. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies // J Clin Invest. 2018 Jul 2;128(7):3041-3052.

83. Hoffman HM, Broderick L. JAK inhibitors in autoinflammation. J Clin Invest. 2018 Jul 2;128(7):2760-2762. doi: 10.1172/JCI121526. Epub 2018 Jun 11.

84. Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther. 2018 Aug;104(2):364-373. doi: 10.1002/cpt.936. Epub 2017 Dec 8.

85. Furie R, Khamashta M, Merrill JT, Werth VP et al. Investigators Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus // Arthritis Rheumatol. 2017 Feb;69(2):376-386.

86. Khamashta M, Merrill JT, Werth VP, Furie P, et al. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study // Ann Rheum Dis. 2016 Nov; 75(11): 1909-1916.

87. Практическое руководство по детским болезням. Под_ред. В.Ф.Кококлиной и А.Г.Румянцева. Иммунология детского возраста. Под ред. А.Ю. Щербины и Е.Д. Пашанова. Медпрактика-М, 2006.

88. Европейский регистр аутовоспалительных заболеваний. Электронный ресурс. Доступ: http s: //www. printo. it/eurofever/

89. Н.Т. Ватутин, А.С. Смирнова, М.А. Эль-Хатиб. Семейная средиземноморская лихорадка: обзор рекомендаций EULAR, 2016. Архивъ внутренней медицины, № 6, 2016: 5-11.

90. Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol. 2018 Oct;11(10):987-998.